Grant S Schulert Selected Research

Macrophage Activation Syndrome

1/2022	Identification of Distinct Inflammatory Programs and Biomarkers in Systemic Juvenile Idiopathic Arthritis and Related Lung Disease by Serum Proteome Analysis.
8/2021	Inflammatory biomarkers in COVID-19-associated multisystem inflammatory syndrome in children, Kawasaki disease, and macrophage activation syndrome: a cohort study.
1/2021	Monocyte and bone marrow macrophage transcriptional phenotypes in systemic juvenile idiopathic arthritis reveal TRIM8 as a mediator of IFN-γ hyper-responsiveness and risk for macrophage activation syndrome.
7/2020	Proceedings from the 2nd Next Gen Therapies for Systemic Juvenile Idiopathic Arthritis and Macrophage Activation Syndrome symposium held on October 3-4, 2019.
2/2020	IL-18 as therapeutic target in a patient with resistant systemic juvenile idiopathic arthritis and recurrent macrophage activation syndrome.
1/2020	Adenosine deaminase 2 as a biomarker of macrophage activation syndrome in systemic juvenile idiopathic arthritis.
1/2020	IL-18 as a biomarker linking systemic juvenile idiopathic arthritis and macrophage activation syndrome.
11/2019	Systemic Juvenile Idiopathic Arthritis-Associated Lung Disease: Characterization and Risk Factors.
1/2019	A Multiparameter Flow Cytometry Analysis Panel to Assess CD163 mRNA and Protein in Monocyte and Macrophage Populations in Hyperinflammatory Diseases.
1/2018	Effect of Biologic Therapy on Clinical and Laboratory Features of Macrophage Activation Syndrome Associated With Systemic Juvenile Idiopathic Arthritis.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Grant S Schulert Research Topics

Disease

14	Juvenile Arthritis (Juvenile Idiopathic Arthritis) 01/2022 - 09/2014
13	Macrophage Activation Syndrome 01/2022 - 04/2014
6	Cytokine Release Syndrome 01/2021 - 04/2014
3	Communicable Diseases (Infectious Diseases) 01/2022 - 11/2020
3	COVID-19 12/2021 - 08/2020
3	Inflammation (Inflammations) 01/2021 - 01/2019
3	Infections 04/2009 - 11/2004
2	Lung Diseases (Lung Disease) 01/2022 - 07/2020
2	Arthritis (Polyarthritis) 01/2019 - 09/2014
2	Fever (Fevers) 02/2018 - 08/2015
1	Eosinophilia 01/2022
1	Mucocutaneous Lymph Node Syndrome (Kawasaki Disease) 08/2021
1	COVID-19 related pediatric multisystem inflammatory disease 08/2021
1	Pain (Aches) 01/2021
1	Hepatitis 07/2020
1	Seizures (Absence Seizure) 02/2018
1	Epilepsy (Aura) 02/2018
1	Drug Resistant Epilepsy 02/2018
1	Adult-Onset Still's Disease 01/2018
1	Rheumatic Diseases (Rheumatism) 01/2018
1	Rheumatoid Arthritis 01/2016
1	Liver Diseases (Liver Disease) 08/2015
1	Pneumonia (Pneumonitis) 11/2014
1	Cystic Fibrosis (Mucoviscidosis) 11/2004
1	Healthcare-Associated Pneumonia 11/2004

Drug/Important Bio-Agent (IBA)

5	Biomarkers (Surrogate Marker)IBA 01/2022 - 09/2014
5	CytokinesIBA 01/2021 - 04/2014
4	Interleukin-1 (Interleukin 1)IBA 07/2020 - 01/2015
4	Interleukin-18 (Interleukin 18)IBA 02/2020 - 01/2015
3	PerforinIBA 12/2021 - 08/2015
3	Biological ProductsIBA 01/2021 - 01/2018
3	MicroRNAs (MicroRNA)IBA 01/2019 - 01/2016
2	InterferonsIBA 01/2022 - 01/2021
2	canakinumab FDA Link 01/2021 - 02/2018
2	Interleukin-6 (Interleukin 6)IBA 07/2020 - 01/2015
1	ProteomeIBA 01/2022
1	Pharmaceutical PreparationsIBA 01/2022
1	HLA Antigens (Human Leukocyte Antigens)IBA 12/2021
1	ABO Blood-Group SystemIBA 12/2021
1	Antiviral Agents (Antivirals)IBA 12/2021
1	S100 Proteins (S 100 Protein)IBA 08/2021
1	S100A12 ProteinIBA 08/2021
1	ChemokinesIBA 01/2021
1	tocilizumab (atlizumab)FDA Link 08/2020
1	Adenosine DeaminaseIBA 01/2020
1	InflammasomesIBA 01/2020
1	Hemoglobins (Hemoglobin)IBA 01/2019
1	AlarminsIBA 02/2018
1	Interleukin 1 Receptor Antagonist Protein (Anakinra)FDA Link 02/2018
1	Scavenger Receptors (Scavenger Receptor)IBA 01/2018
1	Granzymes (Granzyme)IBA 01/2018
1	Anti-Bacterial Agents (Antibiotics)IBA 11/2014
1	Antinuclear AntibodiesIBA 09/2014
1	Interleukin-1beta (Interleukin 1 beta)IBA 04/2009
1	Interleukin-8 (Interleukin 8)IBA 04/2009
1	laminaranIBA 09/2006
1	LigandsIBA 09/2006
1	Mannose ReceptorIBA 09/2006
1	MannansIBA 09/2006
1	Complement Receptors (Complement Receptor)IBA 09/2006
1	dectin 1IBA 09/2006
1	Proteins (Proteins, Gene)FDA Link 11/2004

Therapy/Procedure

5	Therapeutics 07/2020 - 04/2014
3	Critical Care (Surgical Intensive Care) 01/2022 - 11/2020
2	Biological Therapy 11/2019 - 01/2018
1	Injections 09/2014